Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Subjects previously enrolled / randomized in the ReActIF-ICE (Recovery from acute immune failure in septic shock by immune cell extracorporeal terapy - immune competence enhancement) study received either standard sepsis treatment (control group) or standard sepsis treatment and additionally the ARTICE treatment (treatment group) during their index hospitalization. All subjects are followed up for 90 days after enrollment. In this long term follow up study, the enrolled subjects shall be followed up beyond 90 days for up to 5 years.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Subject or legal surrogate is willing and able to provide written willing to sign a consent form and comply with all protocol requirements or the implementation of other established procedures according to the local regulations of the contributing center to include subjects who are unable to provide willing to sign a consent form. 2. Subject was enrolled in the ReActIF-ICE study and successfully passed the Day 2 re-evaluation of that trial. Who Should NOT Join This Trial: - none Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Subject or legal surrogate is willing and able to provide written informed consent and comply with all protocol requirements or the implementation of other established procedures according to the local regulations of the contributing center to include subjects who are unable to provide informed consent. 2. Subject was enrolled in the ReActIF-ICE study and successfully passed the Day 2 re-evaluation of that trial. Exclusion Criteria: * none

Locations (2)

Klinikum Magdeburg, Klinik für Intensiv- und Rettungsmedizin
Magdeburg, Germany
Universitätsmedizin Rostock, Abteilung KAI
Rostock, Germany